News

Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform

May 18, 2021

Oversubscribed round co-led by Cormorant Asset Management and Fairmount Funds, supported by a strong syndicate of new and existing investors

PHILADELPHIA, May 18, 2021 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing. The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital. All existing investors participated, including lead founding investor Tellus BioVentures, the University of Pennsylvania and Penn Medicine, Agent Capital, the Mark Foundation for Cancer Research, Knollwood, and BrightEdge, the American Cancer Society’s impact investment fund. Tomas Kiselak of Fairmount Funds and Ben Lund of Bain Capital Life Sciences will join the Interius Board of Directors.

Full news article can be read here.